Fungal infection drug for lung transplant recipients may increase cancer, death risk
the ONA take:
A prescription drug that is commonly used to treat fungal infections in lung transplant recipients may significantly increase the risk for skin cancer and even death, according to a recent study published in the American Journal of Transplantation.
Researchers led by Sarah Arron, MD, PhD, of the UCSF High Risk Skin Cancer Clinic looked at 455 single-, double- or heart-lung transplant recipients who received their transplant between October 1991 to December 2012.
Patients were analyzed for voriconazole exposure and its impact on cutaneous squamous cell carcinoma and mortality compared to the general population.
They found that exposure to the drug resulted in a 73% greater risk for SCC, with each additional 30-day exposure increasing the risk by 3%.
While the drug significantly reduced risk of Aspergillus colonization, especially within the first year of transplantation along with a reduced all-cause mortality in these patients, it did not reduce risk of aspergillosis.
“It is important for physicians to be aware of the impact of voriconzaole on these outcomes,” said Dr. Arron. “We recommend that all providers counsel lung transplant recipients on skin cancer risk and photoprotection in addition to scheduling routine skin cancer screening with a trained dermatologist after transplantation.”
Prescription drug that is commonly used to treat fungal infections in lung transplant recipients may significantly increase the risk for skin cancer.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Immune Thrombocytopenia (Fact Sheet)
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|